Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Prices of Paracetamol...

    Prices of Paracetamol surge by 40pc as coronavirus shuts China

    Farhat NasimWritten by Farhat Nasim Published On 2020-02-18T13:21:23+05:30  |  Updated On 18 Feb 2020 7:51 AM GMT
    Prices of Paracetamol surge by 40pc as coronavirus shuts China

    Prices of paracetamol, the most commonly used analgesic, have jumped by 40% in India, while the cost of azithromycin, an antibiotic used for treating a variety of bacterial infections, has risen by 70%, said Pankaj R Patel, chairman of Zydus Cadila.

    New Delhi: India is facing the ripple effects of shutdowns in China with the production of medicines being hit as supply chain disruptions prolong.

    Prices of paracetamol, the most commonly used analgesic, have jumped by 40% in India, while the cost of azithromycin, an antibiotic used for treating a variety of bacterial infections, has risen by 70%, said Pankaj R Patel, chairman of Zydus Cadila. The pharma industry could face shortages in finished drug formulations starting April if supplies aren't restored by the first week of next month, he said.

    Also Read: CDSCO Declares 36 Samples Of Atorvastatin, Metformin, Paracetamol, Others As Not Of Standard Quality

    The coronavirus, which has killed more than 1,000 people and stoked fears of a broader slowdown in China, has disrupted global supply lines after factories there slowed production and people were restricted from moving in and out of the country. As manufacturers based in China restart factories, nations such as India that depend heavily on imports of some raw material and intermediate goods from the mainland continue to face uncertainty.

    Patel sees a substantial increase in prices of active pharmaceutical ingredients — the basic substance used to make drugs — in the short- to medium-term. India, one of the largest suppliers of generic drugs to the world and home to about 12% of all manufacturing sites catering to the US market, relies on China for as much as 80% of active pharmaceutical ingredient requirement.

    Also Read: Granules India Gets EIR From USFDA For Paracetamol, Metformin API Manufacturing Plant

    azithromycin paracetamol zydus cadila coronavirus 
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X